Mikhail Blagosklonny is a professor of oncology at the Rosewell Park Cancer Institute in Buffalo, New York. Mikhail Blagosklonny is also a skilled researcher and dedicated philanthropist committed to making the best medical care available to all individuals irregardless of socioeconomic status.Mikhail Blagosklonny has committed much of his life’s work to the research of cancer and aging. More specifically, Dr. Blagosklonny is interested in the connection between the two and the reasons cancer is more prevalent in individuals who have advanced past certain ages. One of his most important contributions to his field of expertise so far is the research he has done on the drug Rapamycin and his subsequent advocacy of the cancer drug’s potential to prolong the life span of the human being.Rapamycin, also known by the name Sirolimus is a pharmaceutical initially used to prevent the rejection of transplanted organs. The drug has also been used to coat coronary stents and the treatment of a rare lung disease. But these uses have proven to be only transparent scratches to the surface in regards to the full scope of Rapamycin’s potential uses:
Superior Immunosuppressant Properties
The body’s natural reaction to organ transplants is to reject the new organ. To prevent this outcome drugs known as Immunosuppressants are prescriptive protocol. Often times these drugs prove detrimental to kidney function. Rapamycin scores well here as the drug has proven to be less toxic to kidneys than other immunosuppressants.
Best Treatment For Patients With Hemolytic-Uremic Syndrome
Hemolytic-Uremic Syndrome is a rare disease caused by the combined effects of anemia, kidney failure, and a low platelet count. This often results in major renal failure. The only options for patients at this point is a lifetime of dialysis or kidney transplantation. When opting for transplants there is a considerable chance that transplanted kidneys will also develop the same disease. Rapamycin greatly lowers this risk.
Used To Treat Lymphangioleiomyomatosis
LAM is a rare disease that usually affects women of childbearing age. Rapamycin has been identified as the primary drug to cure this disease.
Rapamycin is ripe with antiproliferative properties and improves immune response to tumors in the body. Rapamycin has also been proven to promote tumor regression as well. These qualities are reasons the drug is of great use to cancer patients who have had organ transplants.
Increased Life Span Of The Individual
Dr. Mikhail Blagosklonny has completed a considerable amount of research on the potential of Rapamycin to increase human life span. The drug has proven to increase the ability of aging mice to deal with the effects of tuberculosis. Human testing have shown that Rapamycin has the ability to improve immunological rejuvenation in elderly persons when given prior to an influenza vaccination. Though his research has not yet yielded conclusive results, Dr. Mikhail Blagosklonny is in fact convinced that Rapamycin will be proven to to increase the life span of human beings.